SCHEMBL3452482

SCHEMBL3452482

CC(NC(=O)O)C(=O)Nc1ccccc1NC1CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
ALDH1A1 P00352 1/20 0.49
PGR P06401 1/20 0.42
SCN1A P35498 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 3/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13497748 0.85 ALDH1A1 (0.48) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL2510641 0.83 LMNA (0.45) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL13498125 0.82 KMT2A (0.44) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL2508252 0.80 ALDH1A1 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL2507585 0.80 CYP3A4 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL2506898 0.80 PKM (0.44) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL2509380 0.77 CXCR2 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL19949398 0.75 KMT2A (0.49) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL19949399 0.75 KMT2A (0.49) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL11901281 0.75 AAK1 (0.47) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2010-02-04 US disclosed
EP-2094670-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY AstraZeneca AB (SE) 2009-09-02 EP disclosed
WO-2008056150-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY EDF1, ERLIN1, ECE1 CYP3A4 3081/4885CYP2D6 1677/4885CYP2C9 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.